Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052007 | 0.85 | NAPRT (0.72) | NAPRTMEN1KMT2AKDM4ENOTUM | |
| SCHEMBL4322796 | 0.81 | NAPRT (0.68) | NAPRTMEN1KMT2ANOTUMGSK3A | |
| SCHEMBL4849110 | 0.81 | NAPRT (0.68) | NAPRTMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL11005335 | 0.81 | NAPRT (0.68) | NAPRTMEN1KMT2AGSK3AGSK3B | |
| Antipyrine SCHEMBL20452 | 0.81 | NAPRT (1.00) | NAPRTKMT2AKDM4EL3MBTL1GSK3A | |
| SCHEMBL4334502 | 0.80 | NAPRT (0.56) | NAPRTMEN1KMT2AL3MBTL1HTT | |
| Antipyrine SCHEMBL8736656 | 0.79 | NAPRT (0.96) | NAPRTKMT2AKDM4EL3MBTL1GSK3A | |
| Antipyrine SCHEMBL8995343 | 0.79 | NAPRT (0.96) | NAPRTKMT2AKDM4EL3MBTL1GSK3A | |
| Antipyrine SCHEMBL7020007 | 0.79 | NAPRT (0.96) | NAPRTKMT2AKDM4EL3MBTL1GSK3A | |
| Antipyrine SCHEMBL18260589 | 0.79 | NAPRT (0.96) | NAPRTMEN1KMT2AKDM4EGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026938-B | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118026938-A | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-05-14 | — | — | CN | claimed |
| CN-118026938-B | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118026938-A | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110256407-B | Pyrazolone-substituted-3-hydroxyoxindole-containing derivative and preparation method thereof | 赣南师范大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-110256407-A | One kind -3- hydroxyl oxoindole derivative of substitution containing pyrazolone and preparation method | 赣南师范大学 | 2019-09-20 | — | — | CN | disclosed |
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| US-4436717-A | FLUORINATION OF ANTIPYRINE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | NAPRT 2057/4885MEN1 1683/4885KMT2A 4086/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | NAPRT 2063/4885MEN1 3300/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.